Dr Reddy's Laboratories has been buzzing ever since they have successfully coordinated the arrival and commenced the administration of Sputnik V, Russia's Covid-19 vaccine. Dr Reddy's collaboration is turning out to be a success as they are closing in on the popularity of Bharat Biotech's Covaxin and Covishield from Serum Institute of India.
However, with just initial doses being administered only in Hyderabad, Telangana, the Russian jab will take a while to reach all Indian states. The Indian pharma giant is now approaching the Drug Control General of India and other relevant authorities for a waiver for separate clinical trials of the single-dose version of the Sputnik V known as Sputnik Light. The single-dose version is already approved and is coming to the end of its clinical trials in Russia. The partner representative from India for Russian Direct Investment Fund (RDIF) will seek individual permissions from DCGI and other regulators for six other Indian manufacturers that will manufacture Sputnik V locally to be granted permission to start clinical trials for the light(single dose version) along with Dr Reddy's.
Hetero Group is one of those six Indian pharma manufacturers that will manufacture 100 million doses is already given the approval to conduct trials of locally manufactured Sputnik V and compare it with the recently imported vaccine before it can be approved for administration to the people across the country. The progress on Sputnik Light in Russia is considered, and Dr Reddy's will submit a report based on the received data and hope for approval from the relevant authorities.